Side effects or other adverse events · participants at risk of high altitude illness
Acetazolamide may leads to higher adverse events: side effects‐ Follow‐ up: From arrival to 24 hours… compared with placebo (low certainty).
1 finding from 1 review
Incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival to 24 hours later · participants at risk of high altitude illness
Budesonide may leads to lower incidence of acute mountain sickness (AMS)‐ Follow‐ up: From arrival… compared with placebo (low certainty).
1 finding from 1 review
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Overall survival (reported as mortality) · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in overall survival (reported as mortality) compared with no further treatment (low certainty).
1 finding from 1 review
Treatment‐related mortality ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Event‐free survival · high‐risk neuroblastoma patients treated with autologous HSCT
Retinoic acid postconsolidation therapy showed no clear difference in event‐free survival (reported as relapse, disease progression, death… compared with no further treatment (low certainty).
1 finding from 1 review
Early toxicity ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Late toxicity including secondary malignancies ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life ‐ not reported · high‐risk neuroblastoma patients treated with autologous HSCT
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dose reductions · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain ‐ Any grade · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Fatigue · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Headache · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Treatment discontinuation · women with high‐grade VIN
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete response · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in complete response compared with standard induction therapies (low certainty).
1 finding from 1 review
Early toxicities (during preoperative chemotherapy): febrile neutropenia (2 or more episodes), proven fungal infections, septicemia (1 or more episodes), gastrointestinal toxicity (grade 3 or 4), renal toxicity (glomerular filtration rate < 80 ml/... · patients with high‐risk neuroblastoma
1 finding from 1 review
Treatment‐related mortality · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in treatment‐related mortality compared with standard induction therapies (low certainty).
1 finding from 1 review
Overall survival · patients with high‐risk neuroblastoma
Rapid COJEC showed no clear difference in overall survival compared with standard induction therapies (low certainty).
1 finding from 1 review